Cargando…
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
Activation of LXR activity by synthetic agonists has been the focus of many drug discovery efforts with a focus on treatment of dyslipidemia and atherosclerosis. Many agonists have been developed, but all have been hindered due to their ability to efficaciously stimulate de novo lipogenesis. Here, w...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932051/ https://www.ncbi.nlm.nih.gov/pubmed/36817797 http://dx.doi.org/10.3389/fmed.2023.1102469 |